Now Playing
|Videos|August 18, 2022
Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD
After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.
Advertisement
Episodes in this series
Advertisement
Related to this article
Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.
Coral Omene, MD, PhD, discusses the clinical impact of breast cancer disparities and how oncology nurses can support diverse trial recruitment.
Daisy Molina, EdD, MSN, RNC-LRN, discusses listening, honest reassurance, and lifelong communication skills for nurses facing hard conversations.
In 1,071 women diagnosed at 40 or younger, lower income was tied to delayed presentation and younger age to delayed diagnosis.
A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.
Daisy Molina, EdD, MSN, RNC-LRN, explains how nurses can include caregivers in breast cancer care while keeping the patient's voice central.
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Daisy Molina, EdD, MSN, RNC-LRN, details how nursing students learn to deliver hard news with empathy, plain language, and team support.
Advertisement
Advertisement